Blepharitis

Blepharitis, or eyelid margin disease, is a common condition that affects all ages, ethnicities and genders.

Results from a phase 2b single-arm, open-label trial that showed use of TP-03 for Demodex blepharitis was safe and well-tolerated after 4 weeks of treatment with persisting effects for at least 90 days.

Ivermectin-metronidazole combined topical gel therapy successfully treated blepharitis caused by Demodex folliculorum infection, according to study results published in Contact Lens and Anterior Eye.

Ocular rosacea may appear as other complications such as dry eye or blepharitis, and about 20% of patients will have ocular findings before dermatologic evidence of rosacea, according to a study published in the Journal of American Academy of Dermatology.

The Court of Appeals for the Federal Circuit has reversed a lower court’s order regarding BlephEx’s ongoing patent litigation with Myco Industries.

Tobradex ST, a treatment for inflammatory ocular conditions, has been launched in the United States, Eyevance Pharmaceuticals announced in a press release.

Nicox plans to advance a once-daily blepharitis treatment candidate for consideration for a phase 2b clinical trial, the company announced in a press release.

ORLANDO, Fla. – Clinicians should consider rosacea in patients with meibomian gland dysfunction, according to a speaker here at the American Academy of Optometry meeting.

SAN FRANCISCO — At the American Academy of Ophthalmology meeting, Rolando Toyos, MD, discusses his presentation on the findings of how intense pulsed light may treat meibomian gland dysfunction and dry eye.

SAN FRANCISCO — At the American Academy of Ophthalmology annual meeting, Audrey R. Talley Rostov, MD, cornea, cataract and refractive surgeon at Northwest Eye Surgeons, spoke with Ocular Surgery News about updated medical and surgical treatments for dry eye disease and blepharitis. – by Alaina Tedesco